Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (CAMEO-SEMA)

NCT05371496 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05371496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05371496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (CAMEO-SEMA)
Lead sponsor
Mayo Clinic
Phase
Phase 4
Overall status
Completed
Start date
September 6, 2022
Completion date
July 17, 2026
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiomyopathy, heart failure with preserved ejection fraction (hfpef), obesity